Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma

Oncotarget

Volumn 7, Issue 51, 2016, Pages 85502-85514

  Gao, Minna ^a   Zhang, Xiong ^a   Li, Dan ^a   He, Ping ^a   Tian, Wenguang ^a   Zeng, Bo ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; E cadherin; EIF4E; MMP 2; VEGF C

Indexed keywords

GELATINASE A; INITIATION FACTOR 4E; UVOMORULIN; VASCULOTROPIN C; CADHERIN; CDH1 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; TUMOR MARKER; VEGFC PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EIF4E GENE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIGRATION INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN EXPRESSION ASSAY; PROTEIN FUNCTION; TRANSLATION REGULATION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; CELL MOTION; COLORECTAL TUMOR; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; SECONDARY; TIME FACTOR; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, TUMOR; CADHERINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 85007436439     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13453     Document Type: Article

References (33)

1. American Cancer Association. Cancer Facts & Figures 2016 American Cancer Association.
2. Sunavala-Dossabhoy G, Palaniyandi S, Clark C, Nathan CO, Abreo FW, Caldito G. Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer. The Laryngoscope. 2011; 121:2136-2141.
3. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO journal. 1996; 15:1751.
4. de Oliveira AT, Reis RM, Afonso J, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, Longatto-Filho A. Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours. Histology and histopathology. 2011; 26:1499-1507.
5. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. European journal of cancer. 2000; 36:1607-1620.
6. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochimica et biophysica acta. 2004; 1705:69-89.
7. Frugtniet B, Jiang WG, Martin TA. Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis. Breast cancer. 2015; 7:99-109.
8. Pan H, Bachelder RE. Autocrine Semaphorin3A stimulates eukaryotic initiation factor 4E-dependent RhoA translation in breast tumor cells. Experimental cell research. 2010; 316:2825-2832.
9. Wang R, Geng J, Wang JH, Chu XY, Geng HC, Chen LB. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung cancer. 2009; 66:237-244.
10. Matthews-Greer J, Caldito G, de Benedetti A, Herrera GA, Dominguez-Malagon H, Chanona-Vilchis J, Turbat-Herrera EA. eIF4E as a marker for cervical neoplasia. Applied immunohistochemistry & molecular morphology. 2005; 13:367-370.
11. Niu Z, Wang J, Muhammad S, Niu W, Liu E, Peng C, Liang B, Sun Q, Obo S, He Z, Liu S, Zou X, Niu J. Protein expression of eIF4E and integrin alphavbeta6 in colon cancer can predict clinical significance, reveal their correlation and imply possible mechanism of interaction. Cell & bioscience. 2014; 4:23.
12. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 2010; 16:240-248.
13. Tacconi C, Correale C, Gandelli A, Spinelli A, Dejana E, D'Alessio S, Danese S. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. Gastroenterology. 2015; 148:1438-1451 e1438.
14. Ueda M, Hung YC, Terai Y, Kanda K, Kanemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res. 2005; 11:3225-3232.
15. Hisamatsu T, Mabuchi S, Sasano T, Kuroda H, Takahashi R, Matsumoto Y, Kawano M, Kozasa K, Takahashi K, Sawada K, Matsuo K, Tamada Y, Morii E, Kitadai Y, Kimura T. The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer. Clinical & experimental metastasis. 2015; 32:789-798.
16. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pacific journal of cancer prevention: APJCP. 2014; 15:1085-1091.
17. Verma S, Kesh K, Ganguly N, Jana S, Swarnakar S. Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidants. World journal of biological chemistry. 2014; 5:355-376.
18. Lebel R, Lepage M. A comprehensive review on controls in molecular imaging: lessons from MMP-2 imaging. Contrast media & molecular imaging. 2014; 9:187-210.
19. Bodner-Adler B, Bodner K, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. MMP-1 and MMP-2 expression in uterine leiomyosarcoma and correlation with different clinicopathologic parameters. Journal of the Society for Gynecologic Investigation. 2003; 10:443-446.
20. Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osorio H, Licastro D, Bordeira-Carrico R, Jordan P, Lazarevic D, Sanges R, Stupka E, Huntsman D, Seruca R, Oliveira C. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Human molecular genetics. 2012; 21:4253-4269.
21. Shen CH, Wu JD, Jou YC, Cheng MC, Lin CT, Chen PC, Tseng YS, Shi CS, Chen SY, Chang DC, Lee YR. The correlation between TWIST, E-cadherin, and betacatenin in human bladder cancer. Journal of BUON. 2011; 16:733-737.
22. Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E, La Sorda R, Lattanzio R, Rinaldi R, Lunardi M, Frasson C, Modesti F, Ferretti S, et al. An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. British journal of cancer. 2010; 103:1835-1839.
23. Jiang T, Jiang H, Su XM, Zheng L, Li QL, Zhang ZW, Li XC. [Expressions of E-cadherin and alpha-catenin in benign, malignant and metastatic prostate tumors]. Zhonghua nan ke xue = National journal of andrology. 2012; 18:499-503.
24. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer research. 2008; 28:3815-3826.
25. Huang KJ, Sui LH. The relevance, role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Medical oncology. 2012; 29:318-323.
26. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA capbinding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical & experimental metastasis. 2003; 20:265-273.
27. DeFatta RJ, Nathan CO, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. The Laryngoscope. 2000; 110:928-933.
28. Xu T, Zong Y, Peng L, Kong S, Zhou M, Zou J, Liu J, Miao R, Sun X, Li L. Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis. OncoTargets and therapy. 2016; 9:815-822.
29. Khosravi S, Tam KJ, Ardekani GS, Martinka M, McElwee KJ, Ong CJ. eIF4E is an adverse prognostic marker of melanoma patient survival by increasing melanoma cell invasion. The Journal of investigative dermatology. 2015; 135:1358-1367.
30. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene. 2004; 23:3172-3179.
31. Zhou W, Zhu H, Chen W, Hu X, Pang X, Zhang J, Huang X, Fang B, He C. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer gene therapy. 2011; 18:336-345.
32. Staberg M, Michaelsen SR, Olsen LS, Nedergaard MK, Villingshoj M, Stockhausen MT, Hamerlik P, Poulsen HS. Combined EGFR-and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer cell international. 2016; 16:34.
33. Zhao W, Prijic S, Urban BC, Tisza MJ, Zuo Y, Li L, Tan Z, Chen X, Mani SA, Chang JT. Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of Breast Cancer Cells by Reducing Membrane Fluidity. Cancer research. 2016; 76:2037-2049.